Tirzepatide: FDA approves supplemental Mounjaro efficacy application

On 27 August 2026, the U.S. Food and Drug Administration approved a supplemental application for Mounjaro (tirzepatide). The FDA record identified the submission as an efficacy application sponsored by Eli Lilly and Co., but the supplied data did not specify a new indication, patient population, clinical endpoint, or numerical efficacy result.

Background

Tirzepatide is listed in the record under the brand names Mounjaro and Mounjaro KwikPen. The same drug record also includes Zepbound and Zepbound KwikPen as aliases. The data identify this event as an FDA supplemental approval for Mounjaro and classify the application as “Efficacy.” They do not provide additional information about tirzepatide’s drug class, mechanism, dosing, approved uses, or prior regulatory decisions.

Regulatory action

The event was recorded as an FDA approval of a supplemental application associated with NDA 215866. The submission identifier was NDA215866-SUPPL-45. Its raw description was “FDA approved supplemental application for Mounjaro (tirzepatide) — Efficacy.”

The available record establishes that the supplemental application was approved on the event date. It does not state whether the action added an indication, expanded an eligible population, changed labeling, revised efficacy findings, or addressed another efficacy-related regulatory matter.

What this means

The action confirms an FDA approval decision involving Mounjaro and an efficacy-focused supplemental application. However, the supplied event data do not include the application’s clinical evidence, study design, comparator, treatment effect, confidence interval, p-value, or safety findings.

As a result, this record supports reporting the regulatory action but not a more specific claim about clinical benefit. Readers seeking the exact labeling change or supporting efficacy information should consult the FDA application record and any linked regulatory documents. No new indication or population is identified in the supplied data.

Source

Source: U.S. Food and Drug Administration, FDA application overview record for Mounjaro (tirzepatide), supplemental application NDA215866-SUPPL-45, dated 27 August 2026. The authoritative record is hosted at accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA215866.